Methods for treating hypophosphatemic disorders
First Claim
1. A method of treating a hypophosphatemic disorder associated with abnormal fibroblast growth factor 23 (FGF23) levels and/or activity, comprising administering to a subject in need of such treatment an effective amount of an anti-FGF23 antibody, wherein the anti-FGF23 antibody is administered about every two weeks, and wherein the anti-FGF23 antibody comprises the CDR sequences of SEQ ID NO:
- 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, and SEQ ID NO;
6.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
-
Citations
14 Claims
-
1. A method of treating a hypophosphatemic disorder associated with abnormal fibroblast growth factor 23 (FGF23) levels and/or activity, comprising administering to a subject in need of such treatment an effective amount of an anti-FGF23 antibody, wherein the anti-FGF23 antibody is administered about every two weeks, and wherein the anti-FGF23 antibody comprises the CDR sequences of SEQ ID NO:
- 1, SEQ ID NO;
2, SEQ ID NO;
3, SEQ ID NO;
4, SEQ ID NO;
5, and SEQ ID NO;
6. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- 1, SEQ ID NO;
Specification